| Date | Title | Description |
| 24.07.2026 | Pharmaceutical Frontier: Psychedelics Rise, GLP-1s Diversify, Global Innovation Thrives | The pharmaceutical industry undergoes rapid transformation. Big Pharma embraces psychedelic drugs, acquiring key innovators to treat diverse mental health conditions. This signals a new era for depression, PTSD, and anxiety therapies. Concu... |
| 18.07.2026 | Fat cat? Weight-loss drugs may be coming for your overweight pet | Two U.S. biotech companies are testing experimental GLP-1 weight-loss treatments for overweight cats.
It marks one of the earliest attempts to bring the blockbuster drug class into pet medicine.
Analysts say the idea of GLP-1s for animals f... |
| 18.02.2025 | Akston Named Best Start-Up for 2024 in the S&P Global Animal Health Awards | Akston CEO Todd Zion (right) accepts the 2024 Best Start-Up Award from Joseph Harvey, Editor at S&P Global Animal Health
After fully pivoting its focus from human health to animal health in 2022, Akston - the biotech built for pets - ma... |
| 19.11.2024 | Purdue University and Akston Biosciences Bring "First Dose of Hope" in New Cancer Immunotherapy Trial for Dogs with Urinary Bladder Cancer | Millie, a 10-year-old Sheltie, is receiving treatment with the anti-cPD-L1 mAb at the Purdue University Veterinary Hospital. She is pictured with Dr. Deborah Knapp, lead veterinarian on the study.
Study enrolls dogs with urothelial carcinom... |
